Table 1.
Patient characteristics.
| Numbers of patients (%) Total, N = 72 |
|
|---|---|
| Median age at HCT [years] (range) | 58 (36–73) |
| Patients older than 60 years | 27 (38) |
| Female | 21 (29) |
| Male | 51 (71) |
| Karnofsky index at HCT | |
| 100% | 29 (44) |
| 90% | 22 (33) |
| 80% | 14 (21) |
| 70% | 1 (2) |
| Median HCT-CI (range)a | 0 (0–6) |
| Patients with HCT-CI ≥3 | 8 (11) |
| Cytogenetic abnormalities | |
| TP53del/mut | 29 (40) |
| Deletion(11q)/no TP53del/mut | 7 (10) |
| Other/no del(11q), no TP53del/mut | 13 (18) |
| None | 23 (32) |
| Previous lines of therapies, median (range) | 3 (1–8) |
| Idelalisib | |
| Median duration in months (range) | 6 (1–28) |
| Idelalisib as last line prior to HCT | 48 (67) |
| Idelalisib during course of CLL but not as last line | 24 (33) |
| Drug exposure for CLL treatment, N of patients | |
| Chemotherapy naive | 20 (28) |
| Purine analogue therapy | 41 (57) |
| Ibrutinib | 31 (43) |
| Venetoclax | 13 (18) |
| Alemtuzumab | 10 (14) |
| Chemoimmunotherapy sensitivity | |
| Not exposed | 19 (26) |
| Sensitive disease | 33 (45) |
| Poorly responsive/refractoryb | 20 (27) |
| Failure of at least one pathway inhibitor | 46 (64) |
| Status at HCT | |
| Complete remission | 5 (7) |
| Partial remission | 54 (77) |
| Stable or progressive disease | 11 (15) |
| Donor type | |
| HLA-identical sibling | 21 (29) |
| Other (partially) matched related donor | 10 (14) |
| 8/8 HLA-compatible unrelated donor (UD) | 25 (35) |
| HLA-compatible UD, HLA data missing | 12 (17) |
| Partially matched UD | 4 (6) |
| CMV constellation | |
| Donor and recipient CMV neg. | 19 (27) |
| Donor or recipient CMV pos. | 52 (73) |
| Sex constellation | |
| Female patient–female donor | 10 (14) |
| Female patient–male donor | 11 (16) |
| Male patient–female donor | 14 (20) |
| Male patient–male donor | 35 (50) |
| Conditioning regimen | |
| Non-myeloablative based on 2 Gray TBI | 11 (15) |
| Reduced intensity | 47 (65) |
| High-dose therapy | 14 (19) |
| Stem cell source | |
| Peripheral blood stem cells | 67 (93) |
| Bone marrow | 4 (6) |
| Cord blood | 1 (1) |
| GVHD prophylaxis | |
| CSA with/without MTX/MMF | 62 (86) |
| Tacrolimus with/without MTX/MMF | 8 (11) |
| Other | 2 (3) |
| ATG | 39 (54) |
| PTCY | 9 (13) |
| Alemtuzumab | 9 (13) |
N number, HCT hematopoietic cell transplantation, HCT-CI hematopoietic cell transplantation—comorbidity index, CMV cytomegalovirus, GVHD graft-versus-host disease, TBI total body irradiation, CSA cyclosporine A, MTX methotrexate, MMF mycophenolate mofetil, PBSC peripheral blood stem cells, ATG anti-thymocyte globulin, PTCY posttransplant cyclophosphamide.
aInformation on the HCT-CI was not available for 22 patients.
bNo response or re-treatment within 24 months.